Rigel J Kishton
Overview
Explore the profile of Rigel J Kishton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
4633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Islam S, Maeda T, Tamaoki N, Good M, Kishton R, Paria B, et al.
Cancer Res Commun
. 2023 Jun;
3(5):917-932.
PMID: 37377887
Significance: Reprogramming of TIL into iPSC holds great promise for the future treatment of cancer due to their rejuvenated nature and the retention of tumor-specific TCRs. One limitation is the...
3.
Palmer D, Webber B, Patel Y, Johnson M, Kariya C, Lahr W, et al.
Med
. 2022 Aug;
3(10):682-704.e8.
PMID: 36007524
Background: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) fails to consistently elicit tumor rejection. Manipulation of intrinsic factors that inhibit T cell effector function and neoantigen recognition may therefore improve TIL...
4.
5.
Zhang Y, Vu T, Palmer D, Kishton R, Gong L, Huang J, et al.
Nat Med
. 2022 Aug;
28(10):2219.
PMID: 35953723
No abstract available.
6.
Kishton R, Patel S, Decker A, Vodnala S, Cam M, Yamamoto T, et al.
Cell Rep
. 2022 Aug;
40(5):111153.
PMID: 35926468
Adoptive T cell therapies (ACT) have been curative for a limited number of cancer patients. The sensitization of cancer cells to T cell killing may expand the benefit of these...
7.
Zhang Y, Vu T, Palmer D, Kishton R, Gong L, Huang J, et al.
Nat Med
. 2022 May;
28(7):1421-1431.
PMID: 35501486
Despite breakthroughs in cancer immunotherapy, most tumor-reactive T cells cannot persist in solid tumors due to an immunosuppressive environment. We developed Tres (tumor-resilient T cell), a computational model utilizing single-cell...
8.
Kishton R, Vodnala S, Vizcardo R, Restifo N
Curr Opin Immunol
. 2021 Oct;
74:39-45.
PMID: 34710751
The administration of T cells as cellular therapy against advanced cancers has brought clinical benefit to many patients and has progressed the field of cancer research. However, current cell therapy...
9.
Lowder L, Powell M, Miller S, Kishton R, Kelly C, Cribb C, et al.
J Med Chem
. 2021 Aug;
64(17):12651-12669.
PMID: 34415160
We previously described the development of a DNA-alkylating compound that showed selective toxicity in breast cancer cells. This compound contained an estrogen receptor α (ERα)-binding ligand and a DNA-binding/methylating component...
10.
Dersh D, Phelan J, Gumina M, Wang B, Arbuckle J, Holly J, et al.
Immunity
. 2020 Dec;
54(1):116-131.e10.
PMID: 33271120
Tumors frequently subvert major histocompatibility complex class I (MHC-I) peptide presentation to evade CD8 T cell immunosurveillance, though how this is accomplished is not always well defined. To identify the...